CALC (CalciMedica) Short-Term Debt: $2.50 Mil (As of Mar. 2026)


CALC CalciMedica Inc CALC
23 GF Score
Price $0.90
! 2 Warning Signs
View Full Analysis

What is CalciMedica Short-Term Debt?

CalciMedica CALC -7.24% 23 Short-Term Debt is $2.50 Mil as of Mar. 2026. GuruFocus rates CALC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

CalciMedica's Short-Term Debt for the quarter that ended in Mar. 2026 was $2.50 Mil.

CalciMedica's quarterly Short-Term Debt increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($1.25 Mil) and increased from Dec. 2025 ($1.25 Mil) to Mar. 2026 ($2.50 Mil).

CalciMedica's annual Short-Term Debt stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($1.25 Mil).

CalciMedica Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

CalciMedica Short-Term Debt Related Terms

CalciMedica Short-Term Debt Historical Data

* Premium members only.

The historical data trend for CalciMedica's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CalciMedica Short-Term Debt Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 1.25

CalciMedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.25 2.50
CALC
23GF Score
CalciMedica Inc CALC
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $2.50 Mil mean?
CalciMedica (CALC) has a Short-Term Debt of $2.50 Mil as of Mar. 2026.
Is CalciMedica's Short-Term Debt too high?
CalciMedica's current Short-Term Debt is $2.50 Mil. Overall, CalciMedica has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CalciMedica's Short-Term Debt compare to CRIS and ICU?
CalciMedica's Short-Term Debt of $2.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. CalciMedica's current Short-Term Debt is $2.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CalciMedica stock overvalued right now?
CalciMedica (CALC) has a current Short-Term Debt of $2.50 Mil. The current Short-Term Debt is $2.50 Mil. CalciMedica's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For CalciMedica (CALC), the current Short-Term Debt is $2.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CalciMedica Business Description

Address 505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
23GF Score

Get the complete analysis for CALC

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.90
Price